BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1271893)

  • 21. Target cell - substratum interaction. I. Effect of primed lymphocytes on a rat mammary adenocarcinoma tumor cell line.
    David GS; Wiglesworgh CM
    Immunol Commun; 1978; 7(3):337-52. PubMed ID: 77840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological investigation and immunotherapy in patients operated on for breast carcinoma.
    Reynier J; Villet R; Bazin JC; Bizzini B; Gandrille C; Guettier C; Henocq E; Hollmann K; Mogenet M; Pompidou A; Santus JP; Verley JM
    Int Surg; 1982; 67(1):17-24. PubMed ID: 7095998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mediation of immune responses to tumor antigens by immune RNA.
    Pilch YH
    Prog Exp Tumor Res; 1980; 25():163-77. PubMed ID: 6986630
    [No Abstract]   [Full Text] [Related]  

  • 24. Horizons in tumor immunology. A seminar.
    Wilson RE; Alexander P; Rosenberg SA; Simmons RL
    Arch Surg; 1974 Jul; 109(1):17-29. PubMed ID: 4834133
    [No Abstract]   [Full Text] [Related]  

  • 25. Monoclonal antibodies against cell-surface antigens of the metastatic rat 13762NF mammary adenocarcinoma and their cross-reactivity with human breast carcinomas.
    North SM; Steck PA; Nicolson GL
    Cancer Res; 1986 Dec; 46(12 Pt 1):6393-9. PubMed ID: 3779654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suitability of rat mammary adenocarcinoma 13762 as a model for BCG immunotherapy.
    Kreider JW; Bartlett GL; Purnell DM
    J Natl Cancer Inst; 1976 Apr; 56(4):797-802. PubMed ID: 815563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of immunotherapeutic agents on the progression of spontaneously arising, metastasizing rat mammary adenocarcinomas of varying immunogenicities.
    Greager JA; Baldwin RW
    Cancer Res; 1978 Jan; 38(1):69-73. PubMed ID: 618584
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunodeficiency in cancer and the importance of immune evaluation of the cancer patient.
    Hersh EM; Mavligit GM; Gutterman JU
    Med Clin North Am; 1976 May; 60(3):623-39. PubMed ID: 775211
    [No Abstract]   [Full Text] [Related]  

  • 29. Synergism between host anti-tumor immunity and combined modality therapy against murine breast cancer.
    Stolfi RL; Fugmann RA; Stolfi LM; Martin DS
    Int J Cancer; 1974 Mar; 13(3):389-403. PubMed ID: 4822108
    [No Abstract]   [Full Text] [Related]  

  • 30. [Immune surveillance in neoplasms].
    Schneeweiss U
    Z Exp Chir; 1974; 7(4):204-15. PubMed ID: 4440030
    [No Abstract]   [Full Text] [Related]  

  • 31. [Monoclonal antibodies and cancer].
    López González JS; Selman Lama M
    Salud Publica Mex; 1985; 27(3):213-34. PubMed ID: 2996157
    [No Abstract]   [Full Text] [Related]  

  • 32. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
    Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental and clinical trials with BCG immunotherapy.
    Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL
    Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024
    [No Abstract]   [Full Text] [Related]  

  • 35. Antigenic differences among B16 melanoma variants selected for their differing abilities to metastasize: a possible mechanism for effective adjuvant immunotherapy.
    Steele G; Wang BS; Ghavamzadah G; Fallon M; Richie J; Wilson RE; Mannick JA
    J Surg Oncol; 1980; 15(1):71-83. PubMed ID: 6158632
    [No Abstract]   [Full Text] [Related]  

  • 36. Immune RNA therapy for renal cell carcinoma: survival and immunologic monitoring.
    Ramming KP; deKernion JB
    Ann Surg; 1977 Oct; 186(4):459-67. PubMed ID: 907390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical aspects of cancer immunity.
    Moore GE
    Prog Clin Cancer; 1973; 5():107-20. PubMed ID: 4571116
    [No Abstract]   [Full Text] [Related]  

  • 38. Tumor-specific cellular immunity.
    Cohen AM; Burdick JF; Ketcham AS
    J Surg Res; 1971 Aug; 11(8):421-31. PubMed ID: 4936302
    [No Abstract]   [Full Text] [Related]  

  • 39. The immunotherapy of cancer.
    Parker CW
    Pharmacol Rev; 1973 Jun; 25(2):325-42. PubMed ID: 4581047
    [No Abstract]   [Full Text] [Related]  

  • 40. [Immunotherapy of malignant tumors in man].
    Govalle VI
    Vopr Onkol; 1976; 22(3):99-109. PubMed ID: 779262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.